Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions

Parkinson Disease

Interventions

GENETIC

KL002 injection solution

Neurosurgical delivery of KL002 to the brain

Trial Locations (1)

Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

collaborator

R&D Kanglin Biotech

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER